A Case of Fatal Malignant Hyperthermia During Pes Equinovarus Surgery in a Child

Malign hipertermi (MH), çoğunlukla volatil anestezikler ve/veya süksinilkolin gibi depolarizan kas gevşeticilerle tetiklenerek oluşan ve hipertermi, taşikardi, asidoz ve kas rijiditesi ile karakterize genetik bir sendromdur. MH genellikle anestezi indüksiyonunu takiben görülür, ancak girişim süresince ve sonrasında da ortaya çıkabilir. Dört buçuk yaşında erkek olgu pes ekinovarus operasyonu sırasında dirençli yüksek ateş, taşikardi ve end-tidal karbondioksitte yükselme olması üzerine MH düşünülerek çocuk yoğun bakıma alındı. Takibinde hiperkarbi, ateş ve dirençli metabolik asidozu tekrar gelişen olgu, dantrolen sodyum ve destek tedavileri verilmesine rağmen kaybedildi. Bu olgu genel anestezi uygulanan hastalarda ölümcül olabilen MH olasılığını hatırlatmak, çocuk yoğun bakımda izlem ve tedavisini vurgulamak için sunulmuştur. Anahtar Kelimeler: Malign hipertermi, çocuk, dantrolen, çocuk yoğun Malignant hyperthermia (MH) is a genetic syndrome characterized by hyperthermia, tachycardia, acidosis, and muscle rigidity, often triggered by depolarizing muscle relaxants such as volatile anesthetics and/or succinylcholine. MH usually develops following anesthesia induction, but may occur during and after a surgical intervention. A 4.5-year-old boy was admitted to the pediatric intensive care unit considering MH due to persistent fever, tachycardia and end-tidal carbon dioxide elevation which developed during pes equinovarus surgery. In the follow-up, hypercapnia, fever and refractory metabolic acidosis recurred. Despite the administration of dantrolene sodium and supportive treatments, the patient died. This case is presented to remind the possibility of MH which may be fatal in patients receiving general anesthesia and to emphasize the follow-up and treatment of the patients with MH in pediatric intensive care unit.

[1]  P. Hopkins,et al.  Malignant hyperthermia: pharmacology of triggering. , 2011, British journal of anaesthesia.

[2]  A. Urwyler,et al.  Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. , 2010, British journal of anaesthesia.

[3]  Gregory C. Allen,et al.  Clinical Presentation, Treatment, and Complications of Malignant Hyperthermia in North America from 1987 to 2006 , 2010, Anesthesia and analgesia.

[4]  A. Adesanya,et al.  Trends and Outcomes of Malignant Hyperthermia in the United States, 2000 to 2005 , 2009, Anesthesiology.

[5]  E. Lehman,et al.  Cardiac Arrests and Deaths Associated with Malignant Hyperthermia in North America from 1987 to 2006: A Report from The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States , 2008, Anesthesiology.

[6]  K. Domino,et al.  Analysis of the Clinical Variables Associated with Recrudescence after Malignant Hyperthermia Reactions , 2007, Anesthesiology.

[7]  H. Rosenberg,et al.  Orphanet Journal of Rare Diseases BioMed Central Review Malignant hyperthermia , 2007 .

[8]  R. Krivosic-Horber,et al.  Minor increase of endtidal CO2 during sevoflurane‐induced malignant hyperthermia , 2007, Paediatric anaesthesia.

[9]  A. Urwyler,et al.  Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. , 2001, British journal of anaesthesia.

[10]  C. Johnson,et al.  Malignant hyperthermia: a review. , 1992, Journal of perinatology : official journal of the California Perinatal Association.

[11]  A. Ivankovich,et al.  Sevoflurane triggers malignant hyperthermia in swine. , 1981, Anesthesiology.